These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12197408)

  • 1. [Bone changes in multiple myeloma--current etiopathogenic, diagnostic and therapeutic aspects].
    Sakalová A; Mistrík M; Gazová S; Chabronová I; Hrubisko M; Skultétyová D; Mociková H
    Vnitr Lek; 2002 Jul; 48(7):642-8. PubMed ID: 12197408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporosis in multiple myeloma].
    Sakalová A; Herrmann Z; Gazová S; Chabronová I; Dedík L; Mistrík M; Hrubisko M
    Vnitr Lek; 1998 Nov; 44(11):649-53. PubMed ID: 10422504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic bone disease and the role of bisphosphonates.
    Ellis MJ
    Br J Hosp Med; 1996 Oct 2-15; 56(7):339-45. PubMed ID: 8899222
    [No Abstract]   [Full Text] [Related]  

  • 7. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats.
    Elwakkad AS; El Elshamy KA; Sibaii H
    Epilepsy Res; 2008 Jul; 80(1):47-56. PubMed ID: 18455911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone lesion in multiple myeloma].
    Ise M; Takagi T
    Nihon Rinsho; 2007 Dec; 65(12):2224-8. PubMed ID: 18069264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].
    Zhang X; Chang CK; Wu LY; Zhang Z; Zhou LY; Xiao C; Li X
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):660-3. PubMed ID: 22339822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma.
    Pittari G; Costi D; Raballo M; Maulucci L; Baroni MC; Mangoni M
    Acta Biomed; 2006 Aug; 77(2):81-4. PubMed ID: 17172186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
    Kitano M; Ogata A; Sekiguchi M; Hamano T; Sano H
    J Bone Miner Metab; 2005; 23(1):48-52. PubMed ID: 15616894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma: diagnosis and treatment.
    Nau KC; Lewis WD
    Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.